Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Systemic Therapy for Melanoma: ASCO Guideline.

Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P.

J Clin Oncol. 2020 Mar 31:JCO2000198. doi: 10.1200/JCO.20.00198. [Epub ahead of print]

PMID:
32228358
2.

Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study.

Rapport F, Smith AL, Cust AE, Mann GJ, Watts CG, Gyorki DE, Henderson M, Hong AM, Kelly JW, Long GV, Mar VJ, Morton RL, Saw RP, Scolyer RA, Spillane AJ, Thompson JF, Braithwaite J.

BMJ Open. 2020 Feb 27;10(2):e032636. doi: 10.1136/bmjopen-2019-032636.

3.

Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single-centre study.

Young R, Snow H, Hendry S, Mitchell C, Slavin J, Schlicht S, Na L, Hofman MS, Gyorki DE.

ANZ J Surg. 2020 Feb 16. doi: 10.1111/ans.15723. [Epub ahead of print]

PMID:
32064728
4.

Accumulation of CD103+ CD8+ T cells in a cutaneous melanoma micrometastasis.

Hochheiser K, Aw Yeang HX, Wagner T, Tutuka C, Behren A, Waithman J, Angel C, Neeson PJ, Gebhardt T, Gyorki DE.

Clin Transl Immunology. 2019 Dec 25;8(12):e1100. doi: 10.1002/cti2.1100. eCollection 2019.

5.

Systemic therapies for unresectable locoregional melanoma: a significant area of need.

Nan Tie E, Lai-Kwon JE, Gyorki DE.

Melanoma Manag. 2019 Sep 2;6(3):MMT25. doi: 10.2217/mmt-2019-0010. Review.

6.

An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?

Downs JS, Gyorki DE.

Melanoma Manag. 2019 Oct 18;6(3):MMT24. doi: 10.2217/mmt-2019-0011. Review.

7.

Locoregional melanoma: identifying optimal care in a rapidly changing landscape.

Gyorki DE, Zager JS.

Melanoma Manag. 2019 Nov 28;6(3):MMT22. doi: 10.2217/mmt-2019-0014. No abstract available.

8.

Skin colonization with beta papilloma virus drives tissue immunity and resistance to squamous cell cancer.

Hochheiser K, Gyorki DE, Gebhardt T.

Immunol Cell Biol. 2020 Jan;98(1):9-11. doi: 10.1111/imcb.12302. Epub 2019 Nov 20. No abstract available.

PMID:
31749172
9.

The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre.

Nan Tie E, Na LH, Hicks RJ, Spillane J, Speakman D, Henderson MA, Gyorki DE.

Ann Surg Oncol. 2019 Dec;26(13):4673-4680. doi: 10.1245/s10434-019-07965-w. Epub 2019 Oct 22.

PMID:
31641949
10.

Characterizing high-grade serous papillary carcinoma of tunica vaginalis.

Qu LG, Teh J, Mitchell C, Gyorki DE, Hicks RJ, Murphy DG.

Urol Case Rep. 2019 Jun 21;26:100949. doi: 10.1016/j.eucr.2019.100949. eCollection 2019 Sep.

11.

ASO Author Reflections: The Impacts of a Negative Sentinel Lymph Node on Quality of Life.

Banting S, Gyorki DE.

Ann Surg Oncol. 2019 Dec;26(Suppl 3):651-652. doi: 10.1245/s10434-019-07523-4. Epub 2019 Jun 21. No abstract available.

PMID:
31228135
12.

Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patient's Perspective.

Banting S, Milne D, Thorpe T, Na L, Spillane J, Speakman D, Henderson MA, Gyorki DE.

Ann Surg Oncol. 2019 Jul;26(7):2263-2267. doi: 10.1245/s10434-019-07375-y. Epub 2019 Apr 22.

PMID:
31011899
13.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ.

Ann Oncol. 2019 May 1;30(5):804-814. doi: 10.1093/annonc/mdz048.

PMID:
30838379
14.

Ectopic breast cancer in the inguinal region.

Loh Z, Yeo B, Williams DS, Gyorki DE.

Breast J. 2019 Jan;25(1):155-156. doi: 10.1111/tbj.13177. Epub 2018 Dec 27. No abstract available.

PMID:
30592120
15.

Management of in-transit melanoma metastases: a review.

Nan Tie E, Henderson MA, Gyorki DE.

ANZ J Surg. 2019 Jun;89(6):647-652. doi: 10.1111/ans.14921. Epub 2018 Nov 9. Review.

PMID:
30414233
16.

Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre.

Snow HA, Hitchen TX, Head J, Herschtal A, Bae S, Chander S, Chu J, Hendry S, Ngan SY, Desai J, Choong PFM, Henderson M, Gyorki DE.

ANZ J Surg. 2018 Nov;88(11):1151-1157. doi: 10.1111/ans.14842. Epub 2018 Oct 4.

PMID:
30288891
17.

Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma.

Kanatsios S, Melanoma Project M, Li Wai Suen CSN, Cebon JS, Gyorki DE.

J Surg Oncol. 2018 Nov;118(6):915-921. doi: 10.1002/jso.25138. Epub 2018 Sep 9.

PMID:
30196539
18.

Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0176-6.

PMID:
30135555
19.

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, Westwood JA, Sandhu S, Raleigh JM, Behren A, Cebon J, Darcy PK, Kershaw MH, McArthur GA, Gyorki DE, Neeson PJ.

Sci Rep. 2018 Jul 24;8(1):11158. doi: 10.1038/s41598-018-28944-3.

20.

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S.

Nat Med. 2018 Jul;24(7):986-993. doi: 10.1038/s41591-018-0078-7. Epub 2018 Jun 25. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29942092
21.

Management of In-Transit Melanoma: We Need Some High-Quality Data.

Gyorki DE.

J Oncol Pract. 2018 May;14(5):302-303. doi: 10.1200/JOP.18.00215. No abstract available.

PMID:
29746807
22.

Incidental Metastatic Melanoma Identified on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer.

Snow HA, Hofman MS, Mitchell CA, Gyorki DE, Smith MJF.

Clin Nucl Med. 2018 Jul;43(7):509-511. doi: 10.1097/RLU.0000000000002111.

PMID:
29742609
23.

Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma.

Hirshoren N, Olayos E, Herschtal A, Ravi Kumar AS, Gyorki DE.

Otolaryngol Head Neck Surg. 2018 Jan;158(1):122-126. doi: 10.1177/0194599817731735. Epub 2017 Sep 19.

PMID:
28925330
24.

Subungual melanoma: Management in the modern era.

Reilly DJ, Aksakal G, Gilmour RF, Gyorki DE, Chauhan A, Webb A, Henderson MA.

J Plast Reconstr Aesthet Surg. 2017 Dec;70(12):1746-1752. doi: 10.1016/j.bjps.2017.08.001. Epub 2017 Aug 16.

PMID:
28888486
25.

Importance of preoperative diagnosis for management of patients with suspected retroperitoneal sarcoma.

Gyorki DE, Choong PFM, Slavin J, Henderson MA.

ANZ J Surg. 2018 Apr;88(4):274-277. doi: 10.1111/ans.14125. Epub 2017 Aug 2. Review.

PMID:
28768365
26.

When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'.

Gyorki DE, Barbour A, Hanikeri M, Mar V, Sandhu S, Thompson JF.

Australas J Dermatol. 2017 Nov;58(4):274-277. doi: 10.1111/ajd.12662. Epub 2017 Jul 17. Review.

PMID:
28718222
27.

Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.

Matheson JA, Te Marvelde L, Mailer S, Speakman D, Spillane J, Henderson MA, Gyorki DE.

Melanoma Res. 2017 Feb;27(1):43-49. doi: 10.1097/CMR.0000000000000302.

PMID:
27753732
28.

Recent Insights and Advances in the Management of Merkel Cell Carcinoma.

Banks PD, Sandhu S, Gyorki DE, Johnston ML, Rischin D.

J Oncol Pract. 2016 Jul;12(7):637-46. doi: 10.1200/JOP.2016.013367. Review.

PMID:
27407160
29.

Intralesional PV-10 for in-transit melanoma-A single-center experience.

Lippey J, Bousounis R, Behrenbruch C, McKay B, Spillane J, Henderson MA, Speakman D, Gyorki DE.

J Surg Oncol. 2016 Sep;114(3):380-4. doi: 10.1002/jso.24311. Epub 2016 May 30.

PMID:
27237868
30.

Excision margins and sentinel lymph node status as prognostic factors in thick melanoma of the head and neck: A retrospective analysis.

Ruskin O, Sanelli A, Herschtal A, Webb A, Dixon B, Pohl M, Donahoe S, Spillane J, Henderson MA, Gyorki DE.

Head Neck. 2016 Sep;38(9):1373-9. doi: 10.1002/hed.24444. Epub 2016 Mar 25.

PMID:
27014970
31.

Sentinel Lymph Node Biopsy in T4 Melanoma: An Important Risk-Stratification Tool.

Gyorki DE, Sanelli A, Herschtal A, Lazarakis S, McArthur GA, Speakman D, Spillane J, Henderson MA.

Ann Surg Oncol. 2016 Feb;23(2):579-84.

PMID:
26471491
32.

Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication.

He M, Lovell J, Ng BL, Spillane J, Speakman D, Henderson MA, Shackleton M, Gyorki DE.

J Surg Oncol. 2015 Jun;111(8):980-4. doi: 10.1002/jso.23938. Epub 2015 Jun 17.

PMID:
26080731
33.

Sentinel lymph node biopsy for melanoma: an important risk-stratification tool.

Gyorki DE, Henderson MA.

Med J Aust. 2015 Feb 2;202(2):79. No abstract available.

PMID:
25627735
34.

Sentinel lymph node biopsy for melanoma: an important risk-stratification tool.

Gyorki DE, Henderson MA.

Med J Aust. 2014 Oct 20;201(8):442-4. Review. No abstract available.

PMID:
25332022
35.

Current management of advanced melanoma: a transformed landscape.

Gyorki DE, Spillane J, Speakman D, Shackleton M, Henderson MA.

ANZ J Surg. 2014 Sep;84(9):612-7. doi: 10.1111/ans.12673. Epub 2014 May 20. Review.

PMID:
24842394
36.

Incidence and location of positive nonsentinel lymph nodes in head and neck melanoma.

Gyorki DE, Boyle JO, Ganly I, Morris L, Shaha AR, Singh B, Wong RJ, Shah JP, Busam K, Kraus D, Coit DG, Patel S.

Eur J Surg Oncol. 2014 Mar;40(3):305-10. doi: 10.1016/j.ejso.2013.11.017. Epub 2013 Dec 13.

PMID:
24361245
37.

Management of recurrent retroperitoneal sarcoma.

Gyorki DE, Brennan MF.

J Surg Oncol. 2014 Jan;109(1):53-9. doi: 10.1002/jso.23463. Epub 2013 Oct 24. Review.

PMID:
24155163
38.

The delicate balance of melanoma immunotherapy.

Gyorki DE, Callahan M, Wolchok JD, Ariyan CE.

Clin Transl Immunology. 2013 Aug 9;2(8):e5. doi: 10.1038/cti.2013.5. eCollection 2013 Aug. Review.

39.

Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma.

Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE.

Ann Surg Oncol. 2013 Sep;20(9):3106-11. doi: 10.1245/s10434-013-2999-1. Epub 2013 May 17.

40.

Improving the impact of didactic resident training with online spaced education.

Gyorki DE, Shaw T, Nicholson J, Baker C, Pitcher M, Skandarajah A, Segelov E, Mann GB.

ANZ J Surg. 2013 Jun;83(6):477-80. doi: 10.1111/ans.12166. Epub 2013 Apr 26.

PMID:
23617607
41.

Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence.

Gyorki DE, Untch B, Tuttle RM, Shaha AR.

Ann Surg Oncol. 2013 Jul;20(7):2285-9. doi: 10.1245/s10434-013-2897-6. Epub 2013 Feb 16. Review.

PMID:
23417435
42.

Cancer surgery in low-income countries: an unmet need.

Gyorki DE, Muyco A, Kushner AL, Brennan MF, Kingham TP.

Arch Surg. 2012 Dec;147(12):1135-40. doi: 10.1001/archsurg.2012.1265.

PMID:
23248017
43.

Spontaneous bacterial peritonitis: a rare mimic of acute appendicitis.

Preece ER, Athan E, Watters DA, Gyorki DE.

ANZ J Surg. 2012 Apr;82(4):283-4. doi: 10.1111/j.1445-2197.2012.06007.x. No abstract available.

PMID:
22510192
44.

Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14.

Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ, Visvader JE.

Mol Cell Biol. 2011 Nov;31(22):4609-22. doi: 10.1128/MCB.05766-11. Epub 2011 Sep 19.

45.

Management of synchronous tumours of the oesophagus and pancreatic head: a novel approach.

Gyorki DE, Clarke NE, Hii MW, Banting SW, Cade RJ.

Ann R Coll Surg Engl. 2011 Sep;93(6):e111-3. doi: 10.1308/147870811X591675. Review.

46.

Endoscopic management of post-cholecystectomy biliary fistula.

Hii MW, Gyorki DE, Sakata K, Cade RJ, Banting SW.

HPB (Oxford). 2011 Oct;13(10):699-705. doi: 10.1111/j.1477-2574.2011.00353.x. Epub 2011 Jul 19.

47.

Enterocutaneous fistula: a single-centre experience.

Gyorki DE, Brooks CE, Gett R, Woods RJ, Johnston M, Keck JO, Mackay JR, Heriot AG.

ANZ J Surg. 2010 Mar;80(3):178-81. doi: 10.1111/j.1445-2197.2009.05086.x.

PMID:
20575922
48.

Significance of sentinel lymph node micrometastases in patients with breast cancer.

Gyorki DE, Henderson MA.

J Clin Oncol. 2010 Mar 20;28(9):e139; author reply e141-2. doi: 10.1200/JCO.2009.26.1420. Epub 2010 Feb 16. No abstract available.

PMID:
20159811
49.

Resident macrophages influence stem cell activity in the mammary gland.

Gyorki DE, Asselin-Labat ML, van Rooijen N, Lindeman GJ, Visvader JE.

Breast Cancer Res. 2009;11(4):R62. doi: 10.1186/bcr2353. Epub 2009 Aug 26.

50.

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ; kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ.

Nat Med. 2009 Aug;15(8):907-13. doi: 10.1038/nm.2000. Epub 2009 Aug 2.

PMID:
19648928

Supplemental Content

Loading ...
Support Center